Immunic (NASDAQ:IMUX) Earns Outperform Rating from Wedbush

Wedbush reissued their outperform rating on shares of Immunic (NASDAQ:IMUXGet Rating) in a research report report published on Wednesday, Marketbeat reports. They currently have a $11.00 price target on the stock.

IMUX has been the subject of several other reports. Aegis dropped their target price on Immunic from $40.00 to $35.00 and set a buy rating for the company in a research report on Monday, August 8th. SVB Leerink lowered their price objective on Immunic from $45.00 to $9.00 and set an outperform rating for the company in a research report on Friday, June 3rd. Finally, HC Wainwright reissued a buy rating and set a $26.00 price objective on shares of Immunic in a research report on Monday. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $24.00.

Immunic Price Performance

NASDAQ IMUX opened at $3.34 on Wednesday. The company has a market cap of $102.09 million, a P/E ratio of -1.10 and a beta of 1.98. The stock has a 50-day moving average of $4.37 and a two-hundred day moving average of $6.21. Immunic has a 1-year low of $2.52 and a 1-year high of $14.50.

Hedge Funds Weigh In On Immunic

Institutional investors and hedge funds have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Immunic in the first quarter valued at approximately $34,000. MetLife Investment Management LLC acquired a new position in Immunic in the first quarter valued at approximately $134,000. Corton Capital Inc. acquired a new position in Immunic in the second quarter valued at approximately $42,000. Delphia USA Inc. acquired a new position in Immunic in the second quarter valued at approximately $46,000. Finally, JPMorgan Chase & Co. boosted its holdings in Immunic by 21.2% in the first quarter. JPMorgan Chase & Co. now owns 13,649 shares of the company’s stock valued at $154,000 after purchasing an additional 2,387 shares in the last quarter. 59.77% of the stock is owned by institutional investors and hedge funds.

About Immunic

(Get Rating)

Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.

Read More

Analyst Recommendations for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.